Friday, December 12, 2008

Osteoporosis Drug Seems to Shrink Breast Tumors

Researchers continue to test the mettle of breakthrough breast cancer drugs, three decades after tamoxifen changed the medical landscape by drastically reducing the risk of recurrences in women with estrogen receptor-positive tumors. Encouraging findings on several different drugs were presented Thursday at the CTRC-AACR San Antonio Breast Cancer Symposium in Texas.

First in the line-up, the osteoporosis drug zoledronic acid (Zometa) appears to shrink breast tumors in patients who undergo chemotherapy. The drug is already approved to treat breast cancer that has spread to the bone and, earlier this year, was reported to lower the risk of breast cancer recurrence in pre-menopausal women with early estrogen- or progesterone-positive tumors.
read article